10-K: Syndax Pharmaceuticals Reports Strong Product Revenue Growth in 2025

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, reported a net loss of $285.4 million in 2025 despite significant revenue growth from its two FDA-approved cancer therapies, Revuforj and Niktimvo.

Summary

• Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company with two FDA-approved medicines: Revuforj (menin inhibitor) and Niktimvo (CSF-1R blocking antibody).
• Revuforj received FDA approval in November 2024 for relapsed or refractory (R/R) acute leukemia with a KMT2A translocation, and a second approval in October 2025 for R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation.
• Niktimvo was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.
• Net product revenue for Revuforj significantly increased to $124.8 million in 2025 from $7.7 million in 2024.
• Collaboration revenue, representing the company's share of net profits from Niktimvo co-commercialization with Incyte, was $42.4 million in 2025.
• The company reported a net loss of $285.4 million for 2025, an improvement from a $318.8 million net loss in 2024.
• The accumulated deficit reached $1.5 billion as of December 31, 2025.
• Cash, cash equivalents, and short-term investments totaled $394.1 million as of December 31, 2025.
• Ongoing clinical development programs for revumenib include combination therapies in newly diagnosed NPM1m and KMT2Ar AML, and exploration in myelofibrosis (MF).
• Axatilimab is also in development for newly diagnosed cGVHD patients and idiopathic pulmonary fibrosis (IPF).
• Entinostat development has been deprioritized, though it received marketing approval in China in April 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed filing. While the company achieved significant regulatory approvals and strong revenue growth for its newly launched products, it continues to incur substantial net losses and has a large accumulated deficit, indicating ongoing financial challenges despite commercial progress.

Positives

• Revuforj received two FDA approvals: November 2024 for R/R acute leukemia (KMT2A translocation) and October 2025 for R/R AML (NPM1 mutation).
• Niktimvo received FDA approval in August 2024 for cGVHD.
• Net product revenue for Revuforj grew substantially to $124.8 million in 2025 from $7.7 million in 2024.
• Generated $42.4 million in collaboration revenue from Niktimvo co-commercialization in 2025.
• Revuforj and Niktimvo were added to NCCN Clinical Practice Guidelines in Oncology as Category 2A recommendations.
• Strong clinical trial data for revumenib in combination therapies, including the SAVE trial showing a 76% CR rate and 100% MRD negativity among responders in newly diagnosed AML patients.
• Preclinical data supports revumenib's potential for disease-modifying activity in myelofibrosis.
• Entinostat received marketing approval in China in April 2024.
• Management believes existing cash, cash equivalents, and short-term investments ($394.1 million) will fund operations for at least the next 12 months.
• Maintained effective internal control over financial reporting as of December 31, 2025.

Negatives

• Incurred net losses in each period since inception, except 2021, with a net loss of $285.4 million in 2025.
• Accumulated deficit of $1.5 billion as of December 31, 2025.
• Total operating expenses increased significantly to $445.4 million in 2025 from $363.4 million in 2024.
• Royalty interest expense increased substantially to $33.8 million in 2025 from $4.9 million in 2024.
• Interest income decreased to $22.7 million in 2025 from $26.1 million in 2024 due to lower interest rates and a decreased average balance.
• Decided not to pursue further development of revumenib in colorectal cancer (CRC) due to limited anti-tumor efficacy (no clinical response, 10.5% disease control rate).
• Entinostat development has been deprioritized.
• A valuation allowance for the full amount of net deferred tax assets ($339.7 million) indicates uncertainty about realizing future tax benefits.

Risks

• Uncertainty in successfully commercializing Revuforj and Niktimvo in the U.S. and other jurisdictions, potentially failing to generate expected revenues.
• Sales, marketing, and distribution efforts for newly launched products may be unsuccessful or less effective than anticipated.
• Market opportunities for products may be smaller than estimated, adversely affecting revenue and business.
• Significant competition from other biotechnology and pharmaceutical companies could negatively impact operating results.
• Inability to successfully complete clinical development, obtain regulatory approval, and commercialize product candidates would significantly harm business prospects.
• Interim and preliminary clinical trial data may change as more patient data become available, potentially harming business prospects and stock price.
• Potential for additional costs or delays in completing development and commercialization of product candidates.
• Incyte may fail to perform its obligations under the collaboration or may deprioritize axatilimab development.
• Difficulties in patient enrollment for clinical trials could delay or prevent their completion.
• Failure to comply with regulatory requirements or unanticipated problems with approved products may result in adverse actions such as suspension or withdrawal of products, facility closure, or substantial penalties.
• The regulatory approval processes of the FDA and foreign authorities are lengthy, time-consuming, and inherently unpredictable, potentially harming the business.
• Revuforj, Niktimvo, and future products may not achieve adequate market acceptance among physicians, patients, and healthcare payors.
• Reliance on third-party contract manufacturers and Incyte for all raw materials, active pharmaceutical ingredients, and finished product manufacturing and distribution.
• Products and product candidates may cause undesirable side effects (e.g., Revuforj's boxed warning for differentiation syndrome), which could delay or prevent regulatory approval, limit commercial scope, or result in negative consequences post-marketing.
• Uncertainty regarding insurance coverage and adequate reimbursement for newly approved products could limit marketability and revenue generation.
• Continued net losses since inception (except 2021) and anticipated future losses, requiring additional capital.
• Need for additional capital to finance planned operations, which may not be available on acceptable terms, potentially delaying or halting development and commercialization.
• Inability to obtain or protect intellectual property rights could impair competitive position.
• The market price of common stock may be volatile, leading to potential investment losses.
• Potential dilution to stockholders from future equity or debt securities sales or other funding arrangements.
• Unstable market and economic conditions (e.g., geopolitical conflicts, inflation, interest rates) may seriously adversely affect business, financial condition, and share price.
• Changes in tax laws or regulations could materially adversely affect the company.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.
• Involvement in lawsuits to protect or enforce intellectual property, or defending against infringement claims, could be expensive, time-consuming, and unsuccessful.
• Inability to protect confidential information and trade secrets would harm business and competitive position.
• Social media platforms present risks of inappropriate disclosure of non-public information, negative publicity, or non-compliance with regulations.
• Stringent and evolving U.S. and foreign laws, regulations, and contractual obligations related to data privacy and security, including the use of generative AI technologies, could lead to regulatory investigations, litigation, fines, and business disruptions.

Future Outlook

Syndax Pharmaceuticals expects to continue incurring significant losses in the near future as it advances commercialization and development of its approved products and pipeline candidates. The company plans to initiate the RAVEN trial in the second half of 2026 and a proof-of-principle program for revumenib in myelofibrosis in 2026. Topline data for the MAXPIRe trial of axatilimab in IPF is anticipated in Q4 2026, and for axatilimab in newly diagnosed cGVHD in early 2027 (Phase 2) and early 2028 (Phase 3).

Management Comments

• We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies.
• We plan to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline.
• We believe that strong execution of our strategy will position us to realize our mission to extend and improve the lives of cancer patients.
• We believe that by inhibiting CSF-1R activation on monocytes and macrophages, axatilimab also has the potential to be used to treat other fibrotic diseases where monocyte-derived macrophages have been shown to play a significant role.
• We believe that using axatilimab to inhibit the work of monocyte-derived macrophages may provide a differentiated way to treat IPF, and could result in a more pronounced impact on the fibrotic process.
• Management expects to incur substantial losses on the ongoing development of its product candidates and the Company may not achieve positive cash flow from operations in the near future, if ever.
• Management believes that the cash, cash equivalents and short-term investments balances as of December 31, 2025, should enable the Company to maintain its planned operations for at least 12 months from the issuance date of these financial statements.

Industry Context

StockSavvy.ai notes that Syndax Pharmaceuticals operates in a highly competitive biopharmaceutical landscape, particularly in oncology and rare diseases. The company's strategy to leverage first-mover advantage for Revuforj in specific acute leukemia subtypes and differentiate Niktimvo in cGVHD through its mechanism of action (macrophage inhibition) is crucial. The expansion into myelofibrosis and idiopathic pulmonary fibrosis reflects a broader industry trend of exploring approved drug candidates for new indications to maximize market potential. The increasing scrutiny on drug pricing and reimbursement, as highlighted by the OBBBA and IRA, presents a significant challenge for all pharmaceutical companies, potentially impacting future revenue and profitability.

Comparison to Industry Standards

• Revuforj is the first and only FDA-approved treatment for R/R acute leukemia with a KMT2A translocation.
• Revuforj is the first and currently the only therapy FDA approved for both adults and children with R/R NPM1m AML, differentiating it from Komzifti (ziftomenib) which is FDA approved only for adults with R/R NPM1m AML.
• Niktimvo provides a differentiated way to treat cGVHD by inhibiting monocyte-derived macrophages, which is distinct from other approved agents like Imbruvica (ibrutinib), Rezurock (belomosidil), and Jakafi (ruxolitinib) that are believed to exert their effect through Tand B-cells.
• The 75% overall response rate (ORR) for Niktimvo at the approved dose in the AGAVE-201 study for cGVHD is a strong result in a patient population that has failed at least two prior lines of systemic therapy.
• The 76% complete remission (CR) rate and 100% measurable residual disease (MRD) negativity among responders in the SAVE trial for revumenib in newly diagnosed AML patients (NPM1m, KMT2Ar, or NUP98r) are highly competitive results compared to standard intensive chemotherapy.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• The filing mentions collaboration agreements with Incyte Corporation and license agreements with Vitae Pharmaceuticals, Inc. (a subsidiary of AbbVie Inc.), UCB Biopharma Sprl, and Bayer Schering Pharma AG, which involve milestone and royalty payments. These are standard business agreements for a biopharmaceutical company and are disclosed as part of normal operations rather than unusual related-party dealings.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from successful commercialization and pipeline expansion, but also risk of dilution from future capital raises and volatility due to ongoing losses and competitive landscape.
• Employees: Continued investment in R&D and commercial teams, with competitive compensation and benefits, but also subject to potential layoffs or restructuring if business plans are not met.
• Customers (Healthcare Providers/Patients): Access to new FDA-approved therapies (Revuforj, Niktimvo) for serious conditions, but potential for high costs and reimbursement challenges.
• Suppliers/Manufacturers: Continued reliance on third-party contract manufacturers and Incyte, indicating ongoing business for these partners, but also concentration risk.
• Creditors (Royalty Pharma): Secured revenue stream from Niktimvo sales, capped at $822.5 million, providing a predictable return on investment.

Next Steps

• Advance a robust pipeline of frontline trials of revumenib in combination with standard-of-care therapies to support potential additional listings in NCCN Guidelines and/or label expansion opportunities.
• Evaluate opportunities to commercialize Revuforj outside of the United States, potentially on its own or in collaboration with partners.
• Continue to advance clinical development programs designed to unlock the opportunity for Niktimvo to address newly diagnosed patients with cGVHD and other diseases, starting with IPF.
• Leverage technical, clinical, regulatory, and business expertise to license, acquire, and develop additional cancer therapies to expand the pipeline.
• Initiate the RAVEN trial (Phase 2 collaborative trial of revumenib) in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients in the second half of 2026.
• Initiate a program in 2026 designed to generate proof-of-principle clinical data with revumenib in myelofibrosis.
• Expect to report topline data from the MAXPIRe Phase 2 trial of axatilimab in IPF in the fourth quarter of 2026.
• Topline data from the Phase 2 axatilimab in combination with ruxolitinib trial in newly diagnosed cGVHD patients is anticipated in early 2027.
• Topline data from the AXemplify-357 Phase 3 trial of axatilimab in combination with corticosteroids as initial treatment for cGVHD is anticipated in early 2028.

Key Dates

Recommendation

Syndax Pharmaceuticals has achieved significant milestones with two FDA-approved products, Revuforj and Niktimvo, showing strong initial revenue growth. The robust clinical pipeline and positive early data for combination therapies and new indications (MF, IPF) present substantial long-term potential. However, the company continues to incur significant net losses and has a large accumulated deficit, indicating that profitability is not yet in sight. The competitive landscape, regulatory uncertainties, and reliance on collaborations and third-party manufacturing also pose considerable risks. Given the strong product performance and pipeline potential balanced against ongoing financial losses and execution risks, a 'hold' recommendation is appropriate for investors to monitor commercialization success and pipeline progression towards profitability.

Keywords

Syndax Pharmaceuticals, Revuforj, revumenib, Niktimvo, axatilimab, KMT2A translocation, NPM1 mutation, acute leukemia, AML, cGVHD, menin inhibitor, CSF-1R antibody, biopharmaceutical, cancer therapies, FDA approval, clinical trials, myelofibrosis, idiopathic pulmonary fibrosis, IPF, oncology, hematology, drug development, commercialization, SEC filing, 10-K